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Coronary heart disease (CHO) claims approximately 500,000 lives each year,
nearly half of which are women (American Heart Association, 1998). In addition, CHD
ranks as the leading cause of death in postmenopausal women in the United States and
most industrialized countries. With the increase in the elderly population, CHD will
become epidemic unless preventative measures are taken. (Wenger, 1997). Elevated
plasma cholesterol concentration is strongly associated with the narrowing of coronary
arteries by atherosclorosis, which is a primary cause of heart disease (Thomas & Braus,
1998; American Heart Association, 1998).
Studies have shown that women over the age of55 have a greater risk for CHO
due to elevated trigylcerides and low high-density lipoproteins (HDL) concentrations
(Wenger, 1997; Thomas & Braus, 1998). Part of the reason for women's increased risk
ofCHD is the loss of estrogen after menopause, which has a protective effect during
childbearing years. As women approach menopause, risk of heart disease begins to rise
and continues to rise with age (American Heart Association, 1998). For reasons
unknown, estrogen helps protect premenopausal women against heart disease. When
menopause occurs, women's blood lipid concentrations also change. Low density
lipoprotein cholesterol (LOL) and total cholesterol concentrations increase and HOL
concentrations decrease as a direct result ofestrogen deficiency (American Heart
Association, 1998; Thomas & Braus, 1998; Vander Schouw et aI., 1996).
Copper (Cu) is an essential trace element that is needed for cholesterol
metabolism, myocardial contractility, and glucose metabolism (Nath, 1997; Olivaries &
Dauy, 1996). Numerous studies have shown a relationship between cardiovascular
mortality and copper deficiency in both rats and humans (Hoogeveaen et al., 1995; Jalili
et al., 1996: Milne & Nielson, 1996; Olivaries & Uauy, 1996). These studies have shown
that diets low in copper result in increased total cholesterol and LOL cholesterol and
decreased HDL cholesterol concentrations.
According to the Food and Nutrition Board ofthe National Academy of Sciences,
the estimated safe and adequate daily dietary intake (ESADDI) of copper is 1.5-3.0 mg
(Food & Nutrition Board, 1989; Milne, 1994). According to the Food and Drug
Administration's Total Diet Study, Americans' dietary copper intake is less than 80% of
the suggested daily intake (Pennington & Young, 1991). Reiser et aI. reported that the
median copper intake of22 men and women was 0.78 mg, well below the estimated safe
and adequate range (Reiser et at, 1985). The third National Heath and Nutrition
Examination Survey (NHANES III) reported that the mean copper intake of women age
50 to 59 was 1.11 mg/d, which is slightly below the estimated safe and adequate intake
range of 1.5-3.0 mg/d (Alaimo et aI., 1994). With the increased risk ofCHD after
menopause and the risk associated with a diet low in copper, an analysis of the effect ofa
diet adequate in copper on postmenopausal women could provide valuable information
on protection against heart disease.
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Objectives
The objectives of this study were to investigate the effects of twelve week copper
supplementation on serum lipids (total cholestero~ LDL-cholestero~ HDL-cholesterol,
and triglycerides), glucose, insulin, estradiol, apolipoprotein A-I and apolipoprotein B
concentrations in postmenopausal women with elevated cholesterol who were not using
estrogen replacement therapy.
Null Hypotheses
The following null hypotheses were developed for this study:
I. There will be no statistically significant effect due to twelve weeks copper
supplementation on serum tot~ LDL-cholestero~HDL-cholesterol, or
triglyceride concentrations in postmenopausal women.
2. There will be no statistically significant effect due to twelve weeks copper
supplementation on serum glucose and serum insulin concentrations in
postmenopausal women.
3. There will be no statistically significant effect due to twelve weeks copper
supplementation on serum apolipoprotein A-I and apolipoprotein B
concentrations in postmenopausal women.
Assumptions
The following assumptions were made for this research:
1. It was assumed that the subjects took one supplement capsule two times
each day for twelve weeks.
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2. It was assumed that the subjects fasted for 12 hours before each blood
collection.
3. It was assumed that the subjects did not alter their regular exercise or
eating patterns during the course of the study.
4. It was assumed that the subjects did not take any lipid altering medication
or estrogen replacement therapy.
5. It was assumed that the subjects were honest and accurate in reporting
their food intake using the food frequency form.
Limitations
1. The food frequency forms were limited by the subjects' knowledge and
understanding of food composition and portion sizes.
2. The resuhs ofthe study are relevant to this sample group limiting
extrapolation of results to the general population.
3. Dietary intake of other nutrients or trace minerals, such as zinc, might
affect copper absorption or metabolism.
4. Dietary copper intake may have influenced absorption or metabolism of
copper from the supplement.
Thesis Format
The tables and bibliographic citations in this thesis are written in manuscript fonn




Women and Coronary Heart Disease
CHD is the single leading cause of death in America (American Heart
Association, 1998). According to the American Heart Association, nearly 500,000
Americans died ofCHD in 1995. In addition, close to 14 million Americans have a
history of heart attack, angina pectoris or both, and 96.8 million American adults have
blood cholesterol concentrations of200 mg/dl or higher (American Heart Association,
1998). Plasma lipid concentrations are used as predictors of CHD risk, and elevated
plasma total cholestero~ LDL-cholesterol and triglycerides are strongly associated with
the development of CHD (American Heart Association, 1998; Wenger 1998).
While CHD is ranked as the leading cause of death in America, it is also the
largest killer of American women (American Heart Association, 1998; Newman &
Sullivan, 1996; Rose, 1998; Thomas & Braus, 1998; VilLablanca, 1996; Wenger, 1997;
Wenger, 1996). As women approach menopause, the risk of heart disease begins to rise
and continues to rise with age. Data from the Third National Health and Nutrition
Examination Survey (NHANES ill) indicate that among people over age 65, women have
higher blood cholesterol concentrations than men (American Heart Association, 1998).
Wenger reported that two thirds of American women have at least one major risk factor
for CHD, and the number of CHD risk factors increase with age (Wenger, 1997). More
women now die from aU types of cardiovascular diseases and heart attacks than men
(American Heart Association. 1998; Rose, 1998; Wenger, 1998). With the continued
aging ofAmerica and women's increased risk for heart disease with age, CHD will
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probably become epidemic among women unless preventive measures are taken
(Wenger, 1997; Wenger, 1998).
Estrogen and Coronary Heart Disease
The increased risk of CHD in postmenopausal women may be due to estrogen
loss. Estrogen has been identified as a beneficial factor in the prevention of
cardiovascular disease. This protective effect has been implicated through
epidemiological studies that show an increased risk ofCHD in postmenopausal and
ovariectomized women. With menopause, and th~ loss ofestrogen, changes occur in
women's lipid profiles as total cholesterol and LDL-cholesterol concentrations increase
and HDL-cholesterol concentration decrease (Liu & Bac~ 1998; Newman &
Sullivan, 1996; Thomas & Braus, 1998; Villablanca, 1996; American Heart Association,
1998). Women also experience an increase in triglyceride concentration, which when
coupled with other lipid changes with menopause creates a greater risk for CHO (Thomas
& Braus, 1998; ViHablanca, 1996).
Estrogen administered to both pre-and post-menopausal women has been
observed to significantly increase plasma HOL cholesterol, which is known to be
antiatherogenic (Fahraeus & Wallentin, 1983; Prema et al., 1980). Previous studies
involving oral administration of estradiol to premenopausal women have also reported an
increase in HDL cholestero~ which was attributed to an enhanced synthesis of
apolipoprotein A-I (Schafer et aI., 1983; Hazzard et aI., 1984).
Brenner & Koo examined the effect of estradiol on serum HDL cholesterol in
ovariectomized rats. They observed a significant increase in serum total and HDL
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cholesterol in female rats injected daily with 7 J.lgestradiol benzoate in 0.1 ml cottonseed
oiVI00 g body weight for 5 weeks. The authors hypothesized that the observed increase
in plasma HDL cholesterol was due to a decrease in HDL catabolism. This hypothesis
was based on the delayed clearance of radio labeled HDL. The authors also observed a
significant decrease in hepatic lipase activity, which is involved in HDL clearance
(Brenner & Koo, 1988).
Estrogen has also been observed to alter copper status in both humans and
animals. Chilvers et a1. studied the effect ofestrogen on copper status in postmenopausal
women. They observed an increase in plasma total copper concentration in
postmenopausal women who consumed 15 J.lg of ethinyl estradiol daily for 3 months.
The increase in plasma copper concentration was mainly due to an increase in
ceruloplasmin synthesis, the main copper-binding protein (Chilvers et aI., 1985).
Brenner & Koo also observed an increase in serum and hepatic copper
concentrations in rats receiving 7 Ilg estradiol for five weeks (Brenner & Koo, 1988). In
addition, Yang and Koo observed an increase in both serum HOL-cholesterol
concentration and copper status of rats implanted with a 1.5 mg pellet of 17B-estradiol
(Yang & Koo, 1998).
Thus, estrogen may playa protective role against CHD in women through an
increase in HDL-cholesterol concentration and an improvement in copper status.
However, with menopause, women lose the protective effects ofestrogen. Honnone
replacement therapy is often recommended to reduce CHD risk, however for some
women it has been observed to increase cancer risk (Barrett-Conner et aI., 1998). Thus,
7
adequate dietary copper intake may provide postmenopausal women with an alternative
type ofprotection against CHD.
Copper and Coronary Heart Disease
Diets low in saturated fat and cholesterol as well as increased exercise are
beneficial in lowering plasma lipids (Rose, 1998~ Wenger, 1996; American Heart
Association, 1998; Thomas & Braus, 1998). However, other dietary factors including
trace minerals may affect lipid profiles. Numerous studies have established that poor
copper status in both animals and humans increases the risk ofCHD (Reiser et aI., 1985;
Klevay et aI., 1984; Hermann et aI., 1993; Medeiros et aI., 1993). This is of particular
interest because copper intakes are low in typical American diets. Reiser et aI. reported a
six day average copper intake among 22 men and women of 1.0 mg copper/day (Reiser et
aI., 1985). Klevay reported an average daily copper intake of 0.78 mgld among
American adults (Klevay, 1986). Furthermore, NHANES III reported a mean daily
copper intake among women age 50-59 of 1.1 mg (Alaimo et aI., 1994). Older adults are
at particular risk for low mineral intakes (Tripp, 1997). Copper has an estimated safe and
adequate daily intake (ESADDI) of 1.5 to 3.0 mglday (Food & Nutrition Board, 1989).
Thurman & Mooradian cite copper as one of the most frequent dietary deficiencies in the
elderly population (Thurman & Morradian, 1997).
Copper deficiency has been implicated as a contributor to the development of
CHD as it has been shown to produce hypercholesterolemia and alter lipoprotein profiles
in copper deficient humans (Klevay et aI., 1984; Reiser et. al, 1987; Hermann et aI.,
1993). Klevay et aI., studied a young male during induced copper depletion in which the
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subject consumed a diet without copper for 188 days. The authors observed an increase
in total cholesterol and LDL-cholesterol concentrations during copper depletion. Total
and LDL-cholesterol concentrations subsequently decreased during the copper repletio.n
phase of the study where the subject received 3 mg ofcopper twice a day for 39 days
(Klevay et aI., 1984). Reiser et al., also investigated the effects ofcopper depletion on
lipids in 24 males who consumed a copper deficient diet of 0.36 mg/l000 kcal for 11
weeks. In addition to an increase in LDL-cholesterol concentration, Reiser et aI.
observed a decrease in HDL cholesterol concentration with copper depletion (Reiser et
aI., 1987). Hennann et at investigated the relationship between plasma lipids and
mineral intake in 43 adults over fifty years of age. The authors observed elevated
triglyceride concentrations in those adults with diets that contained less than 2/3 of the
ESADDI for copper (Hermann et a1, 1993).
In a human copper supplementation study, Hermann et aI. observed a significant
decrease in plasma total cholesterol, LDL cholesterol, and triglyceride concentrations in
adults over fifty years of age who received a supplement of 3.0 mg copper/d for twelve
weeks (Hermann et a1., 1998). Milne & Neilson did not observe any changes in serum
lipids in a study of 12 postmenopausal women who consumed a copper depletion diet
containing 0.57 mg copper/day for 105 days followed by copper repletion with 2.0 mg
copper/day for 35 days (Milne & Neilson, 1996).
Several studies investigating copper deficiency in animals have also reported
alterations in lipid profiles. Allen & KJevay observed an increase in both HDL and LDL
cholesterol concentrations in rats consuming a copper deficient diet of0.57 tlg/cu/g for
48 days. Although HDL-cholesterol increased 85% in copper deficient rats when the
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HDL bound cholesterol was expressed as a percent of the total plasma cholesterol
concentration, there was a 9.6% decrease in the percent ofcholesterol associated with
HDL. The bulk of the hypercholesterolemia observed in this study came from a 187%
increase in plasma LDL-cholesterol (Allen & Klevay, 1980).
Harvey & Allen also observed a 91 % increase in total cholesterol concentration
and a 13% decrease in HDL-cholesterol concentration in rats consuming a copper
deficient diet for 66 days. They observed a reverse of the normal 2: 1 ratio ofHDL:
(VLDL + LDL) in the copper deficient rats. An increase in plasma triglyceride
concentration in the copper deficient rats was also observed (Harvey & Allen, 1985).
Crosswel & Lei also investigated the effects ofcopper deficiency in rats for seven
weeks. They observed an increase in all lipoprotein concentrations, with the largest
increase occurring in VLDL and LDL concentrations. They also observed a significantly
higher protein and cholesterol concentration in HDL (Crosswel & Lei, 1985).
Lefeve et a1. noted a significant increase in total cholesterol and HDL cholesterol
concentrations in rats consuming a copper deficient diet for six weeks. They also
observed that copper deficient rats had significantly higher Apolipoprotein A-I (Apo A-I)
concentrations in the HDL fraction than the control animals (Lefeve et aI., 1986). Lee &
Koo also observed an increase in total cholesterol with a marked increase in HDL in rats
consuming a copper deficient diet for twelve weeks. They concluded that the
hypercholesterolemia they observed was primarily due to an increase in cholesterol in the
HDL subfraction that contained a large amount of Apo A-I but did not contain Apo E
(Lee & Koo, 1988).
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AI-Othman et al. also reported copper deficiency induced hypercholesterolemia,
characterized by an increase in plasma HDL in rats fed a low copper diet for seven
weeks. They reported an increase in HDL and LDL protein and cholesterol
concentrations as well as an increase in triglyceride concentration in copper deficient rats.
The plasma pool size of protein, triglycerides, phospholipids, LDL-cholesterol. and
HDL-cholesterol significantly increased with copper deficiency. A unifonn increase in
HOL protein and lipid components indicated that there was an increase in the number of
HDL particles but not an increase in the HOL particle size (AI-Othman et aI., 1992).
Lei suggested that the hypercholesterolemia observed in copper deficient animals
may be due to a shift in cholesterol from the liver pool to the plasma pool (Lei, 1978).
Allen & Klevay also suggested that the hypercholesterolemia in copper deficient rats was
due to an increased rate of cholesterol clearance from the liver pool to the plasma pool
(Allen & Klevay, 1978). Shao & Lei demonstrated that cholesterol esters, newly
synthesized from (2-14 C) mevalonate, cleared the liver faster in copper deficient rats
compared to controls (Shao & Le~ 1980).
The role ofregulation enzymes in cholesterol metabolism including hepatic 3-
hydroxyl-3-methylglutaryl coenzyme A (HMGCoA) reductase and lipoprotein lipase
(LPL) activity in copper deficient animals have been examined. HMGCoA reductase is
the rate-limiting enzyme in cholesterol synthesis (Rodwell et al., 1976). LPL is
responsible for the uptake ofcholesterol and triglycerides from lipoproteins into tissues
(Lau & Klevay, 1982). An increase in HMGCoA reductase activity was observed in
copper deficient animals thus enhancing hepatic cholesterol synthesis (Yount et aI., 1990;
Nath., 1997; Sangbae d aI., 1992). A decrease in LPL activity has been observed with
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copper deficiency, which may result in decreased clearance and thus elevated plasma
triglycerides and total cholesterol concentrations (Koo et ai. 1988; Lau & KJevay, 1982).
In a human copper deficiency study, KJevayet al.. observed a decreased lipoprotein lipase
activity. This observation agrees with decreased LPL activity in copper-deficient rats
observed in a previous study (I(1evay et al., 1984).
In addition to the effect on plasma lipid concentrations, copper may have a role in
CHD through its effect on oxidation. It is well accepted that elevated LDL-cholesterol
increases the risk for CHD and oxidation ofLDL-cholesterol further increases that risk.
Copper is a cofactor for a number of important metalloenzymes including CU/Zn
superoxide dismutase (SOD) (Nath, 1997). CU/Zn SOD is a sensitive indicator of copper
status. Changes occur in SOD concentration before changes occur in other indicators
associated with severe copper deficiency such as plasma copper concentration (Milne &
Nielsen., 1996; Reiser et ai., 1985).
SOD along with glutathione peroxidase constitute the primary catalytic defense
against metabolically generated free radicals (Nath, 1997). SOD is found in tissues such
as the liver and erythrocytes with normal ranges for free living subjects of 500-700 J.1g1g
hemoglobin or 30-80 U/l09 erythrocytes. SOD functions to scavenge the intermediates
ofoxygen reduction such as the superoxide radical. In this capacity, SOD is involved in
the prevention of tissue peroxidation, and decreased SOD activity is associated with
enhanced cell damage (Reiser et aI., 1985).
Dietary copper deficiency leads to decreased SOD activity in the liver, aorta,
lung, and erythrocytes, as well as to increased cell membrane lipid peroxidation. In
addition, increased peroxidation is correlated with low SOD and glutathione peroxidase
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activities (O'Dell, 1990; Nath, 1997). Studies have shown that copper deficient tissues
have decreased SOD activity. Jalili et al. observed a decrease in SOD activity in copper
deficient rats fed less than 1.0 mg Cu/kg for 40 days (Jalili et aI., 1996). Prohaska also
observed decreased SOD activity in rats fed a low copper (0.6 ppm) diet for two weeks
(prohaska, 1983). Milne & Nielson studied rats consuming 0.57 mg CuJd for 105 days
followed by repletion with 2.0 mg Cu/d for 35 days. They reported SOD activity
decreased significantly during low copper intake, but did not increase during repletion
(Milne & Neilson, 1996).
Copper is also a component of ceruloplasmin. Ceruloplasmin is a plasma
glycoprotein containing 6 atoms ofcopper that has ferro-oxidase activity. Most copper is
converted to ceruloplasmin and released into the blood where it constitutes 90% of the
plasma copper pool (O'Dell, 1990; Milne, 1994; Nath, 1997, Ehrenwald et aI., 1994, Fox
et a1., 1995). Ceruloplasmin donates copper to nonhepatic tissues for synthesis of
cuproenzmes such as cyctochrome c oxidase, superoxide dismutase and lysyloxidase
(O'Dell, 1990, Harris, 1987). It also has a rolc in copper transport to the heart muscle
and aortic endothelium. In addition, copper from ceruloplasmin is believed to regulate
aortic CU/Zn SOD (Nat~ 1997).
There are conflicting reports on the effect ofcopper intake on ceruloplasmin
activity. Several studies have reportcd that ceruloplasmin activity is depressed with
copper deficiency, but returns to nonnal when copper intake is adequate. Prohaska
observed a decreased ceruloplasmin activity in rats fed a low copper diet (0.6 ppm) for
two weeks (Prohaska, 1983). KJevay et al. studied a young male during induced copper
depletion in which the subject consumed a diet without copper for 188 days. They
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observed a decrease in ceruloplasmin activity during copper depletion and a return to
normal during the copper repletion phase where the subject received 3 mg copper twice a
day for 39 days (Klevay et al., 1984). Milne et al. also observed decreased ceruloplasmin
activity in men consuming a low copper diet (0.89 mglday) for 120 days with a return to
normal with adequate copper intake (Milne et al., 1990). However, in a study ofrats
consuming 0.57 mg copper for 105 day followed by consumption of2.0 mg copper for 35
days, no significant change in ceruloplasmin activity was observed during copper
depletion, but rather ceruloplasmin activity decreased with copper repletion (Milne &
Neilson, 1996).
Diabetes
An estimated 15.7 million people in the U.S. have diabetes, which is ranked as the
seventh leading cause ofdeath in the US. Type 2 diabetes, a metabolic disorder resulting
from the body's inability to make enough or properly use insulin, is the most common
fonn ofdiabetes as it accounts for 90 to 95% of aU cases (American Diabetes
Association, 1998). Type 2 diabetes is considered a strong risk factor for the
development ofCHD. Adults with diabetes are 2-4 times more likely to have heart
diseases, and the prevalence ofCHD with diabetes increases with age. Evidence of
coronary heart disease is present in 75% of diabetes related deaths and in 7.5 to 20 % of
people with diabetes over age 45 (American Diabetes Association, 1998). Elevated blood
glucose concentrations much lower than those necessary to diagnose diabetes are also
associated with an increased risk ofCHD (Gerstein & Yusuf, 1996). Furthermore,
individuals with type 2 diabetes generally have higher triglycerides and lower HDL-
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cholesterol concentrations than individuals without diabetes. Insulin resistance
associated with type 2 diabetes is believed to be a contributing factor to the development
ofhypertriglyceridemia (Syranne & Taskinen, 1997).
The prevalence ofdiabetes as well as the risk for type 2 diabetes increases with
age. There are 6.3 million people age 65 and older that have diabetes and approximately
halfof all cases occur in people over the age of 55 (American Diabetes Association,
1998). People over the age of45, those who are overweight, and people with low HDL-
cholesterol or high triglycerides are at highest risk for type 2 diabetes (American
Diabetes Association, 1998). Unfortunately, diabetes is reaching epidemic proportions
due to the increasing number ofolder Americans and a greater prevalence ofobesity and
sedentary lifestyles. Reducing lifestyle risk factors through weight loss, improved
nutrition and increased physical activity may delay or even prevent the onset of type 2
diabetes (American Diabetes Association, 1998). Trace minerals, in particular copper,
may also have a role in diabetes risk.
Copper and Diabetes
Alterations in copper status have been observed in people with diabetes.
Awadallah et al. reported serum copper concentrations in children with diabetes were
slightly decreased compared to non-diabetic children. They also observed a decrease in
ceruloplasmin concentration in children with diabetes compared to non-diabetic children
(AwadaJlah et aI., 1978). Car et al. observed lower serum copper concentrations in both
non-insulin dependent and insulin dependent diabetics when compared to non-diabetics.
They observed that changes in copper concentrations were not affected by a change in
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glucose concentration in either type ofdiabetes, which suggests that the type ofdiabetes
was not directly responsible for changes in serum copper concentration. They also
observed increased urinary copper excretio~ increased copper absorptio~ and decreased
CuZn SOD activity in diabetic subjects (Car et aI., 1992). In contrast, Rohn et al. did not
observe any differences in serum copper concentrations between 45 diabetic children and
12 non-diabetic children (Rohn et ai., 1993).
Copper deficiency has been shown to playa role in the regulation of glucose
metabolism as it is associated with impaired glucose tolerance and characterized by
increased blood glucose and glucose intolerance (Mertz, 1994). Bhathena et al.
conducted a study with 11 healthy males and 9 carbohydrate sensitive males who
followed a diet containing 1.03 mg copper/d for 11 weeks, followed by a diet of3 mg
copper/d for 3 weeks. They observed a delay in insulin secretion and an increase in
plasma glucagon concentration with the consumption of a marginally deficient copper
diet (Bhathena et al., 1988).
Klevay et al. studied two healthy men who were consuming diets providing 0.7-
0.8 mgld of copper. The subjects were initially supplemented with 0.5 mg copper for 30
days. After which, subjects consumed a copper deficient diet providing 0 mg copper for
120 days, followed by a copper repletion diet providing 3.5 mg copper for 30 days.
Glucose tolerance tests at 20 to 60 minutes post glucose infusion were conducted after 30
days (initial supplementation), after 120 days (depletion) and after 30 days (repletion).
The average insulin concentration at both 20 and 60 minutes post glucose infusion
declined by 10 J..lU/ml during the copper depletion phase and further declined during the
repletion phase. Average serum glucose concentration, however, increased during the
depletion phase and decreased during the repletion phase. Thus it was observed that after
the copper repletion phase, glucose clearance was more rapid, even though insulin
concentration was lower (KJevay et aI., 1983).
Similar fmdings have been observed in several animal studies. Fields et aI.
studied rats fed 1.2 ug copper or 5 ug copper per mg body weight for 9 weeks. They
observed that copper deficiency impaired glucose tolerance in rats fed both glucose and
fructose. An increase in glycosylated hemoglobin, triglycerides and cholesterol was also
observed in the copper deficient fructose fed rats. In addition copper deficiency
decreased insulin binding, lipogenesis, and glucose oxidation (Fields et aI., 1984).
Cohen et a1. observed a delayed plasma insulin response to an oral glucose load in
rats fed a copper deficient diet when compared to rats fed a copper-supplemented diet for
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four months. They also observed a significant increase in plasma glucose concentrations
at 60 and 120 minutes post glucose load in the copper deficient rats compared to the
copper-supplemented rats (Cohen et aI., 1982).
Hassel et al. investigated the effects of rats fed 0.85 mg copper/d or 8.0 mg
copper/d for five weeks. They observed that although there was no difference in the
fasting glucose levels, at 30 minutes after glucose injection the copper deficient rats had
higher plasma glucose concentrations compared to the copper supplemented. After 2
hours there were no significant differences between the two groups. They also
investigated the effects of copper supplementation on plasma insulin concentrations.
They did not observe a significant difference in mean fasting insulin levels between
groups. Plasma insulin concentration peaked at 30 minutes for copper supplemented rats,
but was delayed to 60 minutes for the copper deficient rats. The authors speculated that
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the observed delay in insulin response was responsible for the glucose intolerance
observed in copper-deficient rats (Hassel et aI., 1983). In contrast, Fields et aJ. studied
marginal copper deficient rats consuming 0.6 ug Cu/g for 2 weeks. They reported that
marginal copper deficiency had no effect on either plasma insulin or plasma glucose
concentrations (Fields et aI., 1996).
Abdul-Ghani et al. fed rats Cu(OAc)2 in doses varying from 10 to 100 mg/kg
body mass. They observed copper repletion decreased serum glucose and decreased
insulin concentrations. They reported that copper complexes were more active than
inorganic copper. These complexes facilitate absorptio~ distribution and utilization of
copper, which is essential for activation of copper-dependent enzymes required to
maintain normal physiological processes (Abdul-Ghani et aI., 1996).
Cohen et a1. also observed impaired glucose tolerance and delayed plasma insulin
response to oral glucose load in rats fed a copper poor diet containing 6.7 ppm copper.
They observed that the effect ofcopper on glucose incorporation differed from that of
insulin. However, they observed a synergistic effect as copper enhanced the effect of
insulin. and insulin also enhanced the effect ofcopper. When copper was added to
tissues incubated first by insulin, there was greater glucose incorporation suggesting that
preconditioning cells with insulin was needed for maximal effect ofcopper on glucose
incorporation. They also observed increased insulin binding in the presence of copper
due to an augmented insulin receptor capacity and affinity (Cohen et aI., 1986).
Researchers have also investigated the effect ofcopper on lipogenesis. Following
insulin binding, glucose is transported across the cell membrane where post receptor
processes such as lipogenesis occur. Copper stimulates lipogenesis and glucose oxidase,
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however, copper combined with insulin has been observed to have a greater effect on
glucose incorporation into glycogen and into lipids than copper or insulin alone. Fields et
a1. reported that insulin was required to stimulate copper in order to effect lipogenesis.
They studied copper deficient rats for 7 weeks and found that copper and insulin
combined significantly decreased peak blood glucose at 30 minutes and increased
incorporation ofglucose to lipids due to formation of a more stable complex which
increased insulin binding and or decreased its degradation. This study revealed that
insulin and copper combined significantly decreased blood glucose in vivo and
significantly increased lipogenesis when compared with either copper or insulin alone.
Copper increased insulin binding and stimulated deoxyglucose transport by isolated
adipocytes suggesting that copper may interact with insulin to form a complex which has
greater affinity for a receptor site than insulin alone and or increased the stability of
insulin (Fields et aI., 1983).
In another study, Fields et a1. observed that copper stimulated glucose transport
and increased specific insulin binding in rats. They hypothesized that the increased
insulin binding is due to an increased number of receptor sites (Fields et aI., 1984).
Bhathena et al. studied nine carbohydrate sensitive and eleven normal subjects during
marginal copper depletion and adequate copper intake for fourteen weeks. They reported
increased insulin binding, an increased fasting plasma insulin concentration, and a higher
insulin response to oral glucose in the carbohydrate sensitive subjects regardless of
copper status. They hypothesize that the increased insulin binding was due to an increase
in the number of insulin receptors without a change in their affmity. This suggests that
there was an altered response of the insulin receptor, namely the failure of plasma insulin
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to regulate the number of receptors. They did not observe any effect of copper deficiency
on the number or affmity of insulin receptors even though previous reports have indicated
that copper deficient rats had fewer insulin receptors (Bhatena et aI., 1988).
The selective impairment of glucose induced stimulation of insulin in animals fed
a copper poor diet may involve impairment in glucose metaoolism in the beta cells.
Another probable mechanism of the effect of copper on the penneability of the cell
membrane and coppers oxidative effect is the reduced activity of the oxidative amine
oxidases. Adults with type 2 diabetes appear to have a selective inability to secrete
insulin following glucose stimulation. It is unclear whether this effect is genetically
inherited or acquired. In rats fed a copper poor diet (1.2 ppm) it has been shown that the
defect is not genetically inherited, but may be acquired as a result of changes in
environmental conditions (Cohen & Miller, 1986).
It has been suggested that oxidation of the pancreatic beta cells contributes to the
development of diabetes. CU/Zn SOD may also playa role in the etiology of type 2
diabetes as it provides the body with defense from oxygen radicals and plays a role in
oxidative metabolism. Car et al. observed a lower CulZn SOD concentration in diabetic
subjects compared to healthy subjects (Car et al., 1992). A decrease in CU/Zn SOD
activity has also been reported in both animals and humans with inadequate copper
intake. Furthermore, an enhanced tolerance of pancreatic beta cells to oxidative activity
has been observed in those with copper adequate diets (Kubisch et aI., 1994).
Lipid peroxidation has been implicated in the pathogenesis of many degenerative
disorders such as diabetes. It is known to accelerate aging, cardiovascular and
microvascular lesions in diabetic patients (American Diabetes Association, 1998; Faure
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et aI., 1993). As previously cited, copper through Cu/Zn SOD has an antioxidant effect






This study was approved by the Oklahoma State University Institutional Review
Board for human subject research (Appendix A). Women past menopause with elevated
total cholesterol, who were not taking medication to lower blood cholesterol or estrogen
replacement therapy, were solicited for this study. Subjects were solicited by
announcements through local physicians, college and university mailings, and personal
contacts with churches, senior citizen organizations, and local stores as well as through
flyers distributed throughout the community (Appendix B).
Nineteen subjects volunteered for this study; however, five subjects were not
included in the data analysis. One subject was on estrogen replacement therapy, two
subjects were diabetic, and two subjects were non-compliant taking the supplement. As a
result, data from the remaining fourteen subjects were used in the data analysis. There
were seven subjects in each treatment group (placebo and copper supplemented).
Subjects who volunteered to participate signed an approved informed consent
(Appendix C). They were interviewed individually prior to the onset ofthe study in order
to complete a health questionnaire (Appendix D) and were trained individually by a
registered/licensed dietitian on how to complete a food frequency questionnaire
(Appendix E).
Preparation of Supplements
Supplements for this study were prepared in the Department of Nutritional
Sciences laboratory at OkJahoma State University. Number two gelatin capsules
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(Apothcary Product, Inc., Bumsville, MN) were filled using a gelatin capsule ftller
machine (Quanterron, Inc., Burnsville, MN).
Placebo capsules contained approximately 0.1979 g U.S.P. grade lactose
(Spectrum Quality Product, Inc., Gardene CA). The copper supplementation consisted of
29.47 g U.S.P. grade CuS04.SH20 (professional Compounding Centers of American..
Inc., Houston, TX) in 940.53 g U.S.P. grade lactose, so that 0.194 g ofcopper supplement
mixture was calculated to contain 1.5 mg copper. The lactose and CuS04.5H20 were
mixed together for 8 hours in a ball mixture to obtain a homogeneous distribution of the
copper in the lactose. The copper and placebo supplements were analyzed for copper
content using atomic absorption spectrophotometer, Model 5100 PC (perkin-Elmer
Copr., Norwalk, CT). Ten samples of the copper and placebo mixtures, weighing 0.1 g,
were wet and dry ashed using a modified wet and dry ash procedure (Hill et aI., 1985).
The average analyzed copper content of the placebo was negative 42 J.1g1g supplement
mix. The average analyzed copper content of the copper supplement was 7004 Jlg/g
supplement mixture. Since the analyzed copper concentration was lower than calculated
values, the filled weight of the capsules was adjusted to 0.214 g per capsule in order to
provide 1.5 mg ofcopper per capsule.
Experimental Design
This study followed a pre-test, experimental treatment, post-test design.
Volunteers were screened for serum total cholesterol concentration three weeks prior to
starting the study to ensure subjects had total cholesterol concentrations greater than 200
mg/dL Subjects were randomly assigned to treatment groups. Pre and post-data
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Subjects signed an informed consent at the beginning of the screening, after it was
verbally explained to them by the principal investigator. Subjects also completed a
Health Questionnaire to assess their health status, medication use, and exercise regimens
(Appendix D). Subject's height was measured while standing erect against the wan with
barefoot heels together. A scaled rule attached to the wall was read to the nearest
centimeter. Weight was measured without shoes using a calibrated beam scale
(Continental Health-O-Meter, Chicago, IL). Weight was read to the nearest pound.
Subjects' were trained by a registered/licensed dietitian on how to complete a
modified version ofthe Willetts food frequency questionnaire (Eck et aI., 1991;
Appendix E). Subjects were provided with non-biasing bean bag models to illustrate one
cup, 12 cup, and Y4 cup portion sizes. Wooden blocks were provided to illustrate 3-oz
meat portions.
Subjects received a baseline supplement, which was the lactose placebo, to take
for three weeks between the screen and the pre-data collection in order to allow the
subjects to adjust to taking the study supplements twice a day. Subjects were instructed




At the pre-data collection, subjects brought in a complete one-week food
frequency questionnaire, which reflected their dietary intake for the week before the pre-
data collection. The subjects were then weighed to the nearest pound. Subjects carne to
the pre-data collection following a 12 hour fast, but were instructed to consume water.
Due to variations in plasma mineral concentrations with the time of the day, all blood
collections were performed between 7:30 and 9:30 a.m A licensed phlebotomist drew a
fasting blood sample in two 7.5 ml serum tubes (Monovette, Sarstedt, Newton, NC) using
butterfly needles and trace mineral free syringes. After the blood collection, subjects
were provided with nutritional support in the fonn oforange juice, muffins, and coffee
and were asked to sit for 20-30 minutes.
The subjects were randomly assigned to treatment groups and provided with a one
month supply of the assigned supplement. Subjects were instructed to take two capsules
each day, one in the morning and one in the evening with meals. The second and third
month's supply ofsupplements were delivered individually. The subjects received
$ 50.00 for their participation in the study.
Post-data Collection
At the end of 12 weeks supplementation, subjects returned for the post-collection
following a 12 hour fast. Subjects brought in a completed food frequency questionnaire,
which reflected their food intake for the week prior to the post-collection. A Follow-up
Health Questionnaire was completed to detennine if there were any changes in their
health status or medication usage (Appendix F). Subjects' weight was measured to the
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nearest pound and a licensed phlebotomist drew a fasting blood sample in two 7.5 serum
tubes. Following blood collection, subjects were asked to sit for 20 - 30 minutes where
they were provided nutritional support in the form of orange juice, mutTms, and coffee.
Blood Handling and Storage
The same blood handling techniques were followed at both the pre- and post-data
collections. After drawing the blood, the serum tubes were allowed to sit in an ice bath
for 30 minutes. The tubes were centrifuged using a TJ-6R Tabletop centrifuge (Beckman
Instruments, Inc., Palo, CA) for 20 minutes at 1520 g at 4° C to separate the serum. The
serum was carefully removed with a transfer pipette and transferred into individual
plastic storage containers, covered with parafilm and stored for future analysis as follows:
I. 0.5 ml transferred into a 0.5 m1 FARA tube for LDL cholesterol analysis
2. 0.5 m1 transferred into a 0.5 ml FARA tube for total cholestero~ triglyceride,
apolipoprotein A-I, apolipoprotein B, and glucose analysis
3. 250 ul transferred into a 0.5 rnl FARA tube for HDL cholesterol analysis
4. 250 ul transferred into a 0.5 ml tube for insulin analysis
5. SOD ul transferred into a 0.5 m1 siliconized tube for estradiol analysis
LDL-cholesterol tubes were stored at 4°C and kept for a maximum often days
before analysis. Total cholestero~ HDL-cholestero~apolipoprotein A-I, apolipoprotein





Serum total cholesterol concentration was measured using a quantitative,
photometric determination method using the Roche kit number 44307 (Roche Diagnostic
System, Inc., Montclair, NJ). Total cholesterol concentration was determined by
measuring absorbance at 500 run using the FARA clinical analyzer (COBAS FARA,
Roche Diagnostic System, Inc., Montclair, NJ).
lIDL-cholesteroI
Serum HDL-cholesterol was obtained by a separating reagent for HDL using
Roche kit number 44136 (Roche Diagnostic System, Inc., Montclair, NJ). The addition
ofphysphotungstic acid and magnesium ions to the serum allows chylomicrons, VLDL,
and LDL to precipitate. After certrifugation, onJy the lIDL remains in the supernatant.
HDL-cholesterol concentration was measured using the Roche kit number 44307 (Roche
Diagnostic System, Inc., Montclair, NJ) cholesterol reagent and measured using the
FARA clinical analyzer (COBAS FARA, Roche Diagnostic System, Inc., Montclair, NJ).
LDL-cholesteroI
Serum LOL-cholesterol was obtained by a direct, quantitative determination of
LDL cholesterol in the serum using Roche kit number 47416 (Roche Diagnostic System,
Inc., Montclair. NJ). The LDL cholesterol concentration was measured by performing an
enzymatic cholesterol assay on the filtrate solution and was measured by the FARA




Serum triglyceride concentration was measured using a quantitative,
spectrophotometric detennination method using the Roche kit number 44119 (Roche
Diagnostic System, Inc., Montclair, NJ). Triglyceride concentration was determined by
measuring absorbance at 490-550 om using the FARA clinical analyzer (COSAS FARA,
Roche Diagnostic System, Inc., Montclair, NJ).
Apolipoprotein A-I
Serum Apo A-I concentration was measured using a quantitative,
immunoturbidimetrical determination using the Roche kit number 44162 (Roche
Diagnostic System, Inc., Montclair, NJ). The degree of turbidity was measured at 340
om using the FARA clinical analyzer (COBAS FARA, Roche Diagnostic System, Inc.,
Montclair, NJ).
Apo lipoprotein B
Serum Apo B concentration was measured using a quantitative,
irnmunoturbidimetrical determination using the Roche kit number 44161 (Roche
Diagnostic System, Inc., Montclair, NJ). The degree of turbidity was measured at 340




Serum glucose was measured using a quantitative spectrophometric detennination
method using the Roche kit number 47383 (Roche Diagnostic System, Inc., Montclair,
NJ). The glucose concentration was determined by measuring absorbance at 340 run




Insulin was measured using a double antibody radioimmunoassay (RIA). Insulin
determination is based on the ability ofan antibody to bind a fixed amount radioactive
isotope. Frozen serum samples were thawed and inverted prior to analysis. All tests
were run in duplicate except non-specific binding tubes (NSB), which were run in
quadruplicate. For each sample, duplicate values were averaged. Ifduplicate values
were not within 5%, samples were reanalyzed. The Equate (Equate RIA, South Portland,
:ME) option 1 procedure was followed. Insulin tracer and antiserum were added to all
tubes using an Eppendorf repeating pipette. All tubes were vortexed, covered with
parafilm~ and incubated at room temperature for ten minutes. The supernatant of each
tube was decanted using a blotting technique, so that only the pellet remained. The tubes
were counted for one minute using a gamma counter (Packard Coba II, Auto Gamma,
Packard Instrument Co., Meriden, CT).
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Estradiol
Estradiol was measured using a double antibody radioimmunoassay (RIA).
Insulin detennination is based on the ability ofan antibody to bind a fixed amount
radioactive isotope. Frozen serum samples were thawed and inverted prior to analysis.
All tests were run in duplicate except non-specific binding tubes (NSB), which were run
in quadruplicate. For each sample, duplicate values were averaged. If duplicate values
were not within 5%, samples were reanalyzed. The Equate (Equate RIA, South Portland,
ME) option I procedure was followed. Insulin tracer and antiserum were added to all
tubes using an Eppendorf repeating pipette. All tubes were vortexed, covered with
parafilm, and incubated at room temperature for ten minutes. The supernatant ofeach
tube was decanted using a blotting technique, so that only the pellet remained. The tubes
were counted for one minute using a gamma counter (packard Coba 11, Auto Gamma,
Packard Instrument Co., Meriden, CT).
Food Frequency Questionnaire Analysis
The one week food frequency questionnaires were analyzed and averaged using
the Food Processor Plus Program (version 7.11, ESHA Research, Salem, OR). The same
food codes were used for all subjects. The average dietary data included kilocalories,
protein, carbohydrate, fiber, total fat, saturated fat, copper, and percent ofcalories from




Data were analyzed using the Statistical Analysis System (SAS Inst. Inc., Cary,
NC, 1987) version 6.06, available at Oklahoma State University. Subjects' age, weight,
BM!, average dietary data, and serum measures were compared at baseline using the SAS
general linear model (GLM) procedure to see iftbere were any differences between
groups at baseline. Changes in serum lipids (total cholesterol, LDL-cholestero~ HDL-
cholestero~ Apo A-I, Apo-B, and triglyceride), glucose, insulin and estradiol
concentrations after 12 weeks of supplementation ofcopper were compared to changes in
the placebo group using the SAS GLM procedure. Changes in average dietary data were
analyzed across time within groups using the SAS repeated measures procedure to
determine if there was any change in average dietary intakes across the supplementation




Description of the Subjects
Sample Size
The subjects in this study were free-living volunteers from the community of
Stillwater, Oklahoma and the surrounding area. Nineteen subjects volunteered for this
study; however, five subjects were not included in the data analysis. One subject was on
estrogen replacement therapy, two subjects were diabetic, and two subjects were non-
compliant taking the supplement. As a result, data from the remaining fourteen subjects
were used in the data analysis. There were seven subjects in each treatment group
(placebo and copper supplemented).
Age and Anthroprometric Measurements
Subjects' mean age, height, weight, and body mass index (BMl) are presented in
Table 1. The mean age ofthe placebo group was 58 years, while the mean age of the
copper supplemented group was 59 years. There was no significant difference in age
between the two groups.
Mean body weight for the placebo group was 79.0 kg and 84.0 kg for the copper
supplemented group at baseline. The mean total body weights for both groups was
greater than the reported average total body weight for elderly adults of 68.2 kg
(Deurenberg et aI., 1990). Mean body mass index for the placebo group was 28.6 kg/m2
and 32.8 kg/m2 for the copper supplemented group at baseline. The mean body mass


































aValues with different superscript letters in a row are significantly different at baseline, p
:s 0.05.
*Change in concentration after 12 weeks in copper suppLemented group significantly
different compared to change in placebo after 12 weeks, p:s 0.05.
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(Deurenberg et al., 1990). No significant differences were observed between the groups
at baseline for total body weight or body mass index. Furthermore, no significant
changes in total body weight or body mass index were observed during the twelve weeks
of supplementation.
Dietary Intake
The average seven day dietary food frequency intakes at baseline and after
twelve weeks supplementation are presented in Table II. There were no significant
differences observed in the dietary intakes between the groups at baseline. In addition,
there was no change in dietary intakes within supplement groups over time. There was
however, a close to significant increase in percent of kilocalories from total fat (p=O.06)
for the copper supplement group. Therefore, we presume that the significant changes
observed in this study after twelve weeks supplementation were not due to change in
dietary intake during the study.
The average seven day dietary intake consumed by the subjects in this study
reflects the typical American diet. The placebo group consumed an average copper
intake of 1.0 mg/day and the copper supplemented group consumed an average intake of
1.0 mg copper/day. However, the copper intake for subjects in both groups may be
slightly low due to incomplete data on the copper content of foods in the Food Processor
Database. Out ofan average of43 foods per person, an average of six foods per person
were missing copper values. Using the U.S. Department of Agriculture (USDA) Nutrient
Database for Standard Reference, Release 12, it was determined that on average those




Average Seven Day Dietary Intake l
Placebo Copper
Kilocalories
oWeeks (Baseline) 1835 + 257 1634 + 195-
After 12 Weeks Supplementation 1632 ± 269 1640 + 72
Carbohydrates (g)
oWeeks (Baseline) 213 + 30 197 + 25-
After 12 Weeks Supplementation 201 + 29 186 + 12-
Protein (g)
oWeeks (Baseline) 79 + 11 67 + 10- -
After 12 Weeks Supplementation 71 + 12 64 + 6-
Total Fat (g)
oWeeks (Baseline) 67 + 15 53 + 11
After 12 Weeks Supplementation 61 + 14 72 + 6-
Saturated Fat (g)
oWeeks (Baseline) 24 + 3 21 + 3-
After 12 Weeks Supplementation 20 + 4 23 + 3-
Cholesterol (mg)
oWeeks (Baseline) 214 + 39 220 + 44
After 12 Weeks Supplementation 196 + 31 215 + 19
IMeans ± standard error.
aValues with different superscript letters in a row are significantly different at baseline, p
:s 0.05.
*Concentration after 12 weeks supplementation significantly different compared to
baseline concentration within supplement group, p:::: 0.05.
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TABLE II





After 12 Weeks Supplementation
Copper (mg)
aWeeks (Baseline)
After 12 Weeks Supplementation
% Calories from Carbohydrate
aWeeks (Baseline)
After 12 Weeks Supplementation
% Calories from Protein
a Weeks (Baseline)
After 12 Weeks Supplementation
% Calories from Total Fat
aWeeks (Baseline)
After 12 Weeks Supplementation
% Calories from Saturated Fat
aWeeks (Baseline)

























IMeans ± standard error.
aValues with different superscript letters in a row are significantly different at baseline, p
S 0.05.
*Concentration after 12 weeks supplementation significantly different compared to
baseline concentration within supplement group, p S 0.05.
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Department of Agriculture, 1996). The dietary copper intake ofthe subjects was similar
to the reported average intake of men and women of 1.0 mg copper/day (Reiser et aI.,
1985). Both groups consumed slightly more than the average daily intake of 0.78 mg
copper/day by American adults reported by Klevay (Klevay, 1986). Both groups
consumed slightly less than the average daily intake of 1.1 mg copper/day reported in
NHANES III for women age 50-59 (Alaimo et aI., 1994). While the average dietary
copper intake of both groups is typical of the American diet, both groups consumed less
than the ESADDI range of 1.5 to 3.0 mg copper/day.
Both groups consumed diets that contained less than 300 rng ofcholestero~which
is typical for elderly women. The average dietary cholesterol intake ofthe placebo group
was 214 mg while the intake of the copper supplemented group was 220 mg. The
American Heart Association reports the average dietary cholesterol intake among elderly
women ranges between 220 - 260 mg/day (The Nutrition Committee, 1988).
The placebo group consumed 48% of calories from carbohydrates while the
copper supplemented group consumed 50% ofcalories from carbohydrates. Both groups
consumed diets higher in percent of calories from carbohydrates than the 45.6% intake
reported for women age 50-59 in the 1987-88 Nationwide Food Consumption Survey
(NFCS) (FASEB, 1995). In addition, the subjects consumed diets with percent of
carbohydrates similar to the 49.00.10 reported by the Continuing Survey ofFood Intakes by
Individuals (CSFII) in 1989-91 for women age 50-59 (FASEB, 1995). Both groups
consumed diets in line with recommendations made by the American Heart Association
Nutrition Committee for 45% ofcalories from carbohydrate sources.
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Mean percent daily calories from protein consumed by both groups were similar
to the 18.2% and 17.7% reported for women age 50-59 by NFCS 1987-88 and CSFII
1989-91 respectively (FASEB, 1995). The placebo group consumed 19% of calories
from protein. The copper supplemented group consumed 17% ofcalories from protein.
In addition, the protein consumption of both groups were similar to the American Heart
Association recommendation of 16% ofcalories from protein.
Both groups consumed diets lower in fat than the 36.6% fat intake reported for
women age 50-59 by NFCS 1987-88 (FASEB, 1995). The placebo group consumed 33%
of calories from fat, which is slightly above the recommended fat intake of30% or less of
total caloric intake. The copper supplemented group also consumed 33% ofcalories from
fat. Both groups consumed diets with percent ofcalories from fat similar to the 33.9% of
calories from fat reported for women age 50-59 by CSFII 1989-1991 (FASEB, 1995).
Both groups consumed diets similar to the 11.8% ofcalories from saturated fat
reported for women age 20-59 reported by NHANES III (FASEB, 1995). Yet, both
groups had slightly higher saturated fat intake than recommended. The percent of
calories from saturated fat was 12% in both the placebo and copper supplemented groups.
The recommended percent calories from saturated fat is less than 10% (American Heart
Association, 1998).
Finally, the fiber intake ofboth groups was lower than the 20-30 g recommended
for adults (American Heart Association, 1998). However, the average intake of both
groups was greater than the 13.71 gld reported for women age 50-59 by NHANES III
(FASEB, 1995). The placebo group had an average fiber intake of 17 gld and the copper
supplemented group had an average fiber intake of 15 gld.
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Thus, the diets ofboth groups reflect the typical American diet. Since there were
no significant changes within the two groups over time, we presume that the significant
changes observed in this study after twelve weeks supplementation were not due to their
dietary intake, but rather due to the copper supplementation.
Serum Lipid and Apolipoprotein Concentrations
The effect ofcopper supplementation on serum lipids and apo lipoproteins are
presented in Table ID. At baseline there were no significant differences observed in
serum LDL-cholesterol, HDL-cholesteroL apolipoprotein A-I. or apolipoprotein B
concentrations between the copper supplemented group and placebo group. However,
the copper supplemented group had a significantly higher serum total cholesterol and
triglyceride concentrations than the placebo group at baseline (Table lli).
The initial total cholesterol concentrations for the placebo group was 239 mg/dl
and 292 mg/dl for the copper supplemented group. Both groups had initial total
cholesterol concentration higher than the average total cholesterol concentration of217-
235 mg/dl for women age 45-64 (American Heart Association, 1998).
Both groups' initial LDL-cholesterol concentrations were higher than the
recommended 156 mg/dl for adults age 60-64 (National Cholesterol Education Program,
(993). The initial LDL-cholesterol concentrations were 180 mg/dl and 205 mg/dl for the
placebo and copper supplemented groups respectively. The initial HDL-cholesterol
concentration for both the placebo group and the copper supplemented group was 29




Effect of Copper Supplementation on Serum Lipids and Apolipoproteins I
Placebo Copper
Total Cholesterol (mgldl)
aWeeks (Baseline) 239 + 11 a 292 + 1~b
After 12 Weeks Supplementation 230 + 11 283 + 19
LDL-cbolesterol (rngldl)
oWeeks (Baseline) 180 + 11 205 + 16
After 12 Weeks Supplementation 170 + 12 201 + 19
HDL-cbolesterol (mg/dl)
oWeeks (Baseline) 29 + 2 29 + 5
After 12 Weeks Supplementation 28 + 12 8 + 5-
Triglycerides (mgIdl)
oWeeks (Baseline) 148 + 17 a 289 + 73 b
After 12 Weeks Supplementation 161 + 19 274 + 73
Apolipoprotein A-I (mgldl)
oWeeks (Baseline) 143 + 13 162 + 12-
After 12 Weeks Supplementation 154 + 17 180 + 16-
Apolipoprotein B (mgldl)
oWeeks (Baseline) 133 + 23 158 + 10-
After 12 Weeks Supplementation 119 + 23 171 + 24
IMeans ± standard error.
8Yalues with different superscript letters in a row are significantly different at baseline, p
:s 0.05.
*Change in concentration after 12 weeks in copper supplemented group significantly
different compared to change in placebo after 12 weeks, p.:s 0.05.
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The initial triglyceride concentration of the placebo group was 148 mgIdl and 289
mg/dl for the copper supplemented group. According to the Second Expert Panel on the
Oetectio~Evaluation, and Treatment of High Blood Cholesterol in Adults, the
recommended triglyceride concentration for adults is less than 200 mg/dl (National
Cholesterol Education Program, 1993). The placebo group had an initial triglyceride
concentration below the recommended concentration. The initial triglyceride
concentration of the copper supplemented group was greater than the recommended
concentration.
Both groups' initial apolipoprotein A-I concentrations were within normal
parameters, with an initial concentration of 143 mg/dl and 162 mg/dl in the placebo and
copper supplemented groups respectively. The apolipoprotein B concentration in the
placebo group was 133 mgIdl and within normal parameters. However, the copper
supplemented group had an initial apolipoprotein B concentration of 158 mg/d, which is
slightly above the nonnal range of 60-150 mg/dl (Brewer et aI., 198~).
No significant differences were observed over time between groups in total
cholestero~ HDL-cholesterol, LDL-cholesterol, triglyceride apolipoprotein A-I, or
apolipoprotein B concentrations. Previous human studies ofcopper deficiency have
reported alterations of tota! chol.esterol, HDL-cholestero~ and LOL-cholesterol
concentrations. Klevay et al. reported an increase in total cholesterol and LDL-
cholesterol with copper depletion (Klevay et ai., 1984). Reiser et al. also reported an
increase in LOL-cholesterol concentration with copper deficiency as well as a decrease in
HOL-cholesterol concentration (Reiser et aI., 1987). In addition, Hermann et at.
reported a significant decrease in total cholesterol and LOL-cholesterol concentrations in
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elderly adults suppLemented with 3.0 mg copper/day (Hermann et aI., L998). However,
our fmdings agree with Milne & Neilson who did not observe changes in serum Lipid
concentrations ofpostmenopausal women with supplementation of2.0 mg copper/day
(Milne & Neilson, L996).
A slight decrease in mean serum triglyceride concentration was observed after
twelve weeks copper supplementation; however, the decrease was not significant.
Hermann et aI. observed an elevated triglyceride concentration in aduhs with diets that
contained Less than 2/3 of the ESADDI for copper (Hermann et al., 1993). In a copper
supplementation study, Hermann et aL reported a significant decrease in triglyceride
concentrations ofelderly adults receiving 3.0 mg copper/day (Hermann. et aI., 1998).
Although not significant, after twelve weeks copper supplementation, mean
apolipoprotein A-I concentration in the copper supplemented group increased compared
to the placebo. The increase in apolipoprotein A-I agrees with the observed increase in
HDL-cholesterol concentration.
Serum Glucose, Insulin and Estradiol Concentrations
Subjects' mean serum glucose, insulin, and estradiol concentrations at baseline
and after twelve weeks copper supplementation are presented in Table IV. Initial mean
glucose concentration in the placebo group was 101 mg/dl and is within the normal
parameter. The copper supplemented group had an initial mean glucose concentration of
112 mg/dl, which is slightly higher than normal parameter of70 - 110 mg/dl (Grant &
Dchoog, 1991). There were no significant differences observed between the groups at
baseline for serum glucose concentrations.
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TABLElV
Effect ofCopper Supplementation on Serum Glucose, Insulin and Estradiol I
Glucose (mg/dl)
oWeeks (Baseline)
After 12 Weeks Supplementation
Insulin (JillJ/ml)
oWeeks (Baseline)
After 12 Weeks Supplementation
Estradiol (pglml)
oWeeks (Baseline)















IMeans ± standard error.
aValues with different superscript letters in a row are significantly different at baseline, p
~0.05.
*Change in concentration after 12 weeks in copper supplemented group
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The recommended fasting serum insulin concentration is 10-12 I1IU/ml (Glascow,
1990). The placebo group had an initial insulin concentration of 13 j.1lU/ml, which was
slightly above the recommended concentration. The initial insulin concentration of the
copper supplemented group was higher than recommended. They had an initial insulin
concentration of22 IlIU/ml. There was a significant difference observed between the
placebo and copper supplemented groups at baseline for serum insulin concentration with
the copper group having a significantly higher insulin concentration at baseline.
The nonnal estradiol concentration in postmenopausal women is less than 30
pg/ml (Wallach, 1996). Both groups had initial estradiol concentrations above the normal
estradiol concentration. The placebo group had a mean initial estradiol concentration of
70 pg/ml. The initial mean estradiol concentration of the copper supplemented group was
85 pg/ml. In both groups six out of seven subjects had initial estradiol concentrations
greater than 30 pg/ml. It appears that the subjects were in the early stages of menopause.
There was no significant difference between the placebo and copper supplemented
groups at baseline for serum estradiol concentrations.
In this study, twelve weeks ofcopper supplementation resulted in a significant
decrease in serum insulin concentrations compared to the placebo group (Table IV).
There was no significant change in estradiol concentrations after twelve weeks of copper
supplementation compared to the placebo group.
Although not significant, the tendency towards a decrease in serum glucose in the
copper supplement group observed in this study was similar to the findings of other
studies. Bhathena et al. reported an increase in th.e plasma glucose concentrations in
adults consuming a marginally copper deficient diet (1.03 mg/day) (Bhathena et aI.,
44
1988). Hassel et al. reported an increase in plasma glucose concentrations at 30 minutes
post glucose injection in copper deficient rats (Hassel et aI., 1993). Fields et aI. however,
did not observe an effect on glucose concentrations in rats consuming a marginal copper
deficient diet for two weeks (Fields et ai., 1996).
A significant decrease was observed in serum insulin concentrations in this study.
Klevay et al. also observed a decrease in the average insulin concentrations ofadults
during the copper repletion phase of their study (Klevay, 1986). This observation is
similar to reports from animals studies that investigated the effect ofcopper on insulin
concentration. Alxiul-Ghani et aI. conducted a copper supplementation study with rats
and observed a decrease in serum insulin concentration during copper repletion (Alxiul-
Ghani et aL, 1992). Cohen et aL observed delayed plasma insulin responses to oral
glucose loads in copper deficient rats (Cohen et aI., 1982). Hassel et al. also observed a
delay in the peak insulin concentration to 60 minutes in copper deficient animals (Hassel
et aI., 1983). However, Fields et aI. did not observe an effect on plasma insulin





This study investigated the effects of twelve weeks copper supplementation on
serum lipids, apolipoproteins, glucose, insulin and estradiol concentrations in
hypercholesterolemic postmenopausal women not using estrogen replacement therapy.
The subjects in this study were free-living volunteers from the community of Stillwater,
Oklahoma. Subjects were randomly assigned to either the copper supplement group or
the placebo group. The placebo group (n=7) consumed lactose placebo for twelve weeks.
The copper group (n=7) consumed a total of3.0 mg copper daily as copper carbonate for
twelve weeks. Subjects consumed independently chosen diets throughout the study.
Subjects participated in three data collections: screening, baseline, and after
twelve weeks ofcopper supplementation. Serum lipids (total cholesterol, HDL-
cholesterol, LDL-cholesterol, and triglycerides), apolipoproteins (apolipoprotein A-I and
apolipoprotein B), glucose, insulin and estradiol were measured at baseline and after
twelve weeks ofsupplementation. Changes in serum concentrations after twelve weeks
ofsupplementation were compared using the SAS GLM procedure. Significance level
was set at PSO.05.
Dietary intakes from average seven day food frequencies were obtained at
baseline and after twelve weeks supplementation. Seven day food frequencies were
analyzed and averaged using Food Processor. The average dietary data included
kilocalories, protein, carbohydrate, fiber, total fat, saturated fat, copper intake and the
percent daily calories from carbohydrates, protein, fat, and saturated fat. The average
dietary intakes at baseline were compared to the average dietary intakes after twelve
46
--
weeks of supplementation within groups to detennine if any changes in dietary intake
occurred during the supplementation period.
In this study a slight, but not significant decrease in serum triglyceride
concentration; a slight, but not significant increase in apolipoprotien A-I concentration;
and a slight, but not significant decrease in glucose concentration were observed after
twelve weeks of copper supplementation compared to the placebo group. A significant
decrease in serum insulin concentration was observed in the copper supplemented group
after twelve weeks ofcopper supplementation when compared to the placebo group.
There were no significant changes observed in dietary intake.
Test ofNull Hypothesis
The null hypotheses were tested based on the results from this study.
Ho 1: There will be no statistically significant effects due to twelve weeks of copper
supplementation on serum total cholesteroL LDL-cholestero~ HDL-cholesteroL or
triglyceride concentrations in postmenopausal women.
There were no significant effects on serum total cholestero~ LDL-cholesterol,
HDL-cholestero~or triglyceride concentrations in postmenopausal women due to
twelve weeks ofcopper supplementation. Therefore, the researchers failed to
reject null hypothesis one.
lIo 2: There will be no statistically significant effects due to twelve weeks of copper
supplementation on serum glucose or insulin concentrations in postmenopausal women.
A slight but not significant decrease in serum glucose concentration was observed
after twelve weeks of copper supplementation. In addition, twelve weeks of
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copper supplementation significantly decreased serum insulin concentrations in
postmenopausal women. Therefore, null hypothesis two is rejected.
Ho 3: There will be no statistically significant effects due to twelve weeks ofcopper
supplementation on serum apolipoprotein A-lor apolipoprotein 8 concentrations in
postmenopausal women.
There were no significant effects on serum apolipoprotein A-lor apolipoprotein
8 concentrations in postmenopausal women due to twelve weeks of copper
supplementation. Therefore, the researchers failed to reject null hypothesis three.
Limitations
1. The food frequency forms were limited by the subjects' knowledge and
understanding of food composition and portion sizes.
2. The results ofthe study are relevant to this small sample group, one cannot
extrapolate the results of this study to the population as a whole.
3. Dietary intake ofother nutrients or trace minerals, such as zinc, might
affect copper absorption or metabolism.
4. Dietary copper intake may have influenced absorption or metabolism of
copper from the supplement.
5. The Food Processor Database did not contain complete data on the copper
content of foods.
6. Subjects self reported their menopausal status. Estradiol concentrations




women. It is assumed most women were in the early stages of
menopause.
Implications
In this study, after twelve weeks ofcopper supplementation a decrease, although
not significant in serum glucose was observed and a significant decrease in serum insulin
concentration was observed. Thus, adequate copper intake may be particularly important
for individuals with abnormal glucose tolerance, or those at risk for type 2 diabetes.
Recommendations
This study focused on the effect of copper supplementation in postmenopausal
women with elevated total cholesteroL who were not taking medication to lower blood
cholesterol or estrogen replacement therapy. It was however, difficult to obtain an
adequate sample from this population. Estrogen replacement therapy is a common
among postmenopausal women. Regardless of the number of factors indicating the need
for research on this population group, future research on the male population is
recommended.
The greatest response to copper supplementation was observed in serum insulin
concentrations. In addition, although not significant, a decrease in serum glucose
concentrations was observed after twelve weeks ofcopper supplementation. Future
research should focus on the effect of copper supplementation on serum insulin and
glucose in a larger sample. An investigation on the effect of copper supplementation on
individuals with type 2 diabetes and those in a pre-diabetic state would be beneficial.
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Did you know that the risk of heart disease increases for
women after menopause?
Would you like to know ifadequate chromium and copper lower blood cholesterol and
heart disease risk among women after menopause?
Volunteers will receive $50 for participating in this study.
We have an opportunity for women if you are:
• Past menopause
• Have a blood cholesterol level over 240 mg/dl
• Not using estrogen replacement therapy
• Not using medications to lower blood cholesterol
This study will investigate the effects and interactions of chromium and copper
supplementation on the risk of cardiovascular disease in post menopausal women. The
aims of this study are to detennine if twelve weeks supplementation with chromium,
copper or a combination ofchromium and copper lowers blood cholesterol and other
indicators of heart disease risk in post-menopausal women.
Volunteers will be given either a placebo, chromium, copper, or a combination of
chromium and copper. Volunteers will be asked to take one supplement each morning
and one each evening with meals for twelve weeks. The total daily intake is 3 mg copper
and 200 ug/day chromium, which are the upper level of the safe and adequate intake
range for each nutrient, as set by the National Research.
Volunteers will participate in fasting blood and early morning urine collections. A light
breakfast will be served after the fasting blood collection. Volunteers will also
participate in routine measurements ofwrist, waist and hip circumferences, skin fold,
height and weight. Volunteers will be asked to keep diet records before blood
collections.
This study has been approved by the Institutional Review Board For Protection Of
Human Subjects at Oklahoma State University and is funded by the Oklahoma center For
the Advancement of Science and Technology.
Sound like fun??? If you are interested or for further information please contact:
Janice R Hermann, PhD, RDILD
Andrea B Arquitt, PhD, RDILD
Department ofNutritional Sciences









Individual's Consent to Participate in Research
Women's Cholesterol Study: Effects and interactions ofchromium and copper on lipid
metabolism in hypercholesterolemic post menopausal women
I, , voluntarily agree to participate in the above titled
rese~ch which is sponsored by Agriculture Experiment Station, College ofHuman
EnvIronmental Sciences at Oklahoma State University.
I understand that:
(1) the purpose of the study is the measure the effects of mineral supplementation on
plasma lipids and trace mineral status in post menopausal women;
(2) I will receive supplement containing ONE ofthe following:
(a) 0.25 mg lactose as a placebo
(b) 1.5 mg copper
(c) 100 ug chromium
(d) 1.5 mg copper plus 100 ug chromium
(3) I will take one supplement with each morning and evening meal for 12 weeks;
(4) I will not take any new vitamin or mineral supplement other than those that are part
oftms study;
(5) a phlebotomist will draw fasting blood samples of30 ml (about 6 teaspoons) by
venipuncture at the beginning and end of the study, and that slight bruising or discomfort
may result from the venipuncture;
(6) my blood will only be used for the study protocal, and any remaining blood tissue
will be discarded and no further tests will be run.
(7) a urine sample will be collected at the beginning and end of the study;
(8) routine data will be collected or measured for age, height, body weight, wrist, waist
and hip circumferences at the beginning and end of the study;
(9) I will complete a Health Questionnaire concerning health conditions, medication use,
vitamin and mineral supplement use and exercise practices at the beginning of the study;
and a follow-up health and exercise questionnaire after each month of supplementation;
(10) I will complete a 7 day food frequency questionnaire at the beginning and end of
supplementation;
(11) as a reward for participation and as an incentive to complete the study, I will receive
$25 at both the beginning and end blood colJections.
(12) all records are confidential and that my name will not be associated with any reports
or data records at the end of the study;
(13) participation is voluntary and that I have the right to withdraw from this study at
any time by contacting the principal investigators;
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(14) I ~l withdraw from the project if I need to begin taking medication for my health
dunng this study~
P5) this research is beneficial to the public in that the risk cardiovascular disease
Increases among women after menopausal
(16) I may contact Dr Janice Hermann or Dr Andrea Arquitt or Dr Barbara Stoecker at
(405) 744-5040 should I wish further information. I may also contact the office of
University Research Services, 001 Life Sciences East, Oklahoma State University,
Stillwater, OK 74078 telephone (405) 744-5700.
I have read and fully understand the consent form. I sign it freely and voluntarily. A
copy has been given to me.
Date _ Time, _
Signed _
I certify that I have personally explained all elements of this form to the subject before
requesting the subject to sign it.
Signed -:-----:-_::-:--__---:-_---:----:~~---_=____~-------­









1. Subject Number _
2. Date of Birth-------
3. Do you have or have you had any of the following conditions?












4. Do you currently take any medications on a regular basis? No__ Yes_
Specify all medications taken on a regular basis:
Name How often per day Or per week
Name How often per day Or per week
Name How often per day Or per week
Name How often per day Or per week
Name How often per day Or per week
Name How often per day Or per week
Name How often per day Or per week
5. What types of exercise do you do 00 a regular basis?
How many times a week do you exercise? _









Code Number---- Date. _
Vitamin and Mineral Supplement
1. Do you take any vitamin or mineral supplement(s)? Yes _No_
2. If Yes, please, list all names of vitamin or mineral supplements, and how
often do you take the supplement(s)?
Name How often __ per day Or __ per week
Name How often __ per day Or __ per week
Name How often __ per day Or __ per week
Name How often __ per day Or __ per week
Name How often __ per day Or __ per week
Seven Day Food Frequency Questionnaire
This questionnaire asks you about your consumption of foods and beverages
over the past week. The "How Often" columns are for day, week, or
rarely/never. We want you to think back over the past week and tell us how
many times (per day or per week) you consumed each item. A medium
serving is in parentheses.
EXAMPLES:
Ate 1/2 grapefruit about twice last week.
Ate 1 large hamburger four times last week.
Drank 2 cups ofwhole milk each day.
Type of Food How Often Size
(Medium Serving) Day Week Rarely! S M L
Never
Grapefruit (1/2) 2 X
Hamburger, regular (1 patty, 4 X
30z)
Whole milk (1 cup, 8 oz) 2 X
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Type of Food How Often Size
(Medium Serving) Day Week Rarelyl S M L
Never
DAIRY FOODS
Whole milk (1 cup, 8 oz)
2% milk (lcup, 8 oz)
Skim milk (1 cup, 8oz)
Cream, whipped (1 Tbsp)
Sour cream (1 Thsp)
Coffee cream (1 Tbsp)
Ice cream (Yi cup)
Low fat ice cream (Yi cup)
Frozen yogurt (Vi cup)
Yogurt (1 cup)
Low fat yogurt (1 cup)
Cottage cheese (Yi cup)
Cream cheese (1 oz)
Low fat cream cheese (1 oz)
Other cheese (1 slice or 1 oz)
Low fat cheese (1 slice or 1 oz)
Margarine (1 tsp)
Butter (l tsp)
Reduced fat margarine (1 tsp)
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Type of Food How Often Size
(Medium Serving) Day Week Rarely! S M L
Never
FRUITS, FRUIT JUICES






Apples, applesauce or pears
(1 fresh, ~ cup)
Apple juice (Yi cup)
Oranges
Orange juice (Yi cup)
Grapefruit (Yi cup)
Grapefruit juice (Yi cup)





Peaches (1 fresh, Y2 cup canned)
Apricots (1 fresh, Yi cup
canned)
Plums (1 fresh, Yi cup canned)
Honeydew melon (14 melon)
7\
--
Type of Food How Often Size





Tomato juice (~ cup)
Tomato sauce (~cup)
Spaghetti sauce (~ cup)
Red chili sauce, taco sauce, or
salsa (I Tbsp)
Tofu or soybeans (3-4 oz)






Brussels sprouts (~ cup)
Carrots, raw (~ carrot or 2-4
sticks)
Carrots, cooked (~ cup)
Corn (1 ear or ~ cup frozen or
canned)
Peas (Y2 cup fresh, frozen or
canned)
Lima beans (~ cup froze~ or ,
canned)
Mixed vegetables (~ cup)
Beans or lentils, baked or dried
(12 cup)
Summer or yellow squash
(~cup)
Winter squash (~ cup)
Zucchini (Y2 cup)
Yam or sweet potato (12 cup)
Spinach, (cooked Y2 cup, raw 1
T2
cup)




Alfalfa sprouts (~ cup)
Kale, mustard, or chard greens
(~ cup)
Vegetable, vegetable beef,





Type of Food How Often Size




Chicken or turkey, roasted or
broiled with skin (3-4 oz)
Chicken or turkey, roasted or
broiled skinless (3-4 oz)
Chicke~ fried with skin (3-4oz)
Bacon (2 slices)
Hot dogs (2)
Low fat hot dogs (2)
Sausage (2 patties or 2 links)
Bologna (1 slice)
Other processed luncheon meat
(1 slice)
Liver, chicken or beef (3-4 oz)
Hamburger, regular (1 patty,
3-4oz)
Hamburger, lean (1 patty,
3-4oz)
Meat loaf (3-4 oz) ___·_0 _____. .
. Pork, chops, roasts (3-4 oz)
-
Lamb (3-4 oz)
Beef, roast, steak (3-4 oz)
Beef stew with vegetables
(1 cup)
Ham (3-4 oz)
Tuna fish (3-4 oz)
Tuna salad (Y2 cup)
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Fish, baked or broiled (3-4 oz)




Mixed dishes with cheese(1cup)
Lasagna or meat pasta dishes
(1 cup)
Type of Food How Often Size




Cold breakfast cereal (1 cup)
Cold breakfast cereal-fortified
(1 cup)
Cooked oatmeal (1 cup)
Other cooked breakfast cereal
(1 cup)
White bread (1 slice)
Pita bread (1 piece)




Hamburger or hotdog bun (1)
Muffin (1)
Biscuit (1)
Com bread, com muffin (1)
Brown rice (1 cup)
White rice (1 cup)
Spaghetti noodles (1 cup)
Macaroni noodles (1 cup)
Other pasta noodles (1 cup)
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Bulgar, kasha, couscous (1 cup)
Pancakes or waffles (2)
Potatoes, french fries or fried
(~ cup)
Potatoes, baked or boiled (1)
Mashed potatoes (1 cup)
Potato chips or com chips
(small bag or I oz)
Saltine crackers (5)
Saltine crackers, low sodium (5)
Saltine crackers, fat free (5)
Other crackers (5)
Other crackers, low fat (5)
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Type of Food How Often Size
(Medium Serving) Day Week Rarelyl S M L
Never
BEVERAGES
Regular soft drink (1)
Diet soft drink (I )
Caffeine free soft drink (1)
Caffeine free, Diet soft drink
(1)
Lemonade or other non-
carbonated drink (1 glass,
bottle, or can)
Coffee (1 cup)
Decaffeinated coffee (1 cup)
Tea (1 cup)
Herbal tea (1 cup)
Beer (1 glass, bottle, or can)
Red wine (4 oz glass)
White wine (4 oz glass)
Whiskey, g~ or other liquor
(1 drink or shot)
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Type of Food How Often Size




Chocolate (1 small bar or 1 oz)
Candy bar (1 small bar)
Candy without chocolate (1 oz)
Cookies) home baked (2)
Cookies, ready made (2)
Brownies (2)
Doughnuts (2)
Cake, home baked (l slice)
Cake, ready made (1 slice)
Sweet roll, coffee cake, or other
pastry ready made (1 serving)
Sweet roll, coffee cake) or other
pastry home baked (1 serving)
Pie, homemade (1 slice)
Pie, ready made (1 slice)
Jam, jelly, preserves, syrup, or
Honey (1 Tbsp)
Peanut butter (1 Tbsp) --
Popcorn (1 cup)
-----
Popcorn, air popped (1 cup)
Nuts (small packet or 1 oz)
Bran, added to food (1 Thsp)
Wheat germ (1 Tbsp) ---
Chowder or cream soup (1 cup) --
Oil and vinegar dressing (1
Tbsp)
Mayonnaise or other creamy
salad dressing (I Thsp)









I. Have you had a cold in the last month? No _
IF YES, when?
how long did it last?
did you have a fever?
2. Have you had the flu in the last month? No _
IF YES, when?
how long did it last?
yes. _
yes, _
did you have a fever?
3. Have you had any other illness in the last month? No _
IF YES, when?
how long did it last?
did you have a fever?
yes _
4. IfYES TO ANY OF QUESTIONS 1-3, did you continue to take your supplement
during the illness? No Yes _
5. Did your exercise pattern change in the last month? No _ Yes_
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